ACE and diabetic kidney disease: With the standard therapy of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), combined with glucose, lipid, and blood pressure control [15], the outcome for patients with diabetic nephropathy remains poor [16].